The challenge in curing every child with cancer is that every child’s cancer is different. This means that a treatment that works for one child may not work for another. The answer to reaching a 100% survival rate lies in understanding the individual biology of each child’s tumour, and using this as the basis for clinical trials and targeted treatments that lead to more effective cancer control and improved outcomes long term.
Personalised medicine and cancer
Personalised medicine (also known as precision medicine) is all about tailoring treatment to suit each individual patient, based on the bedrock of an understanding of the unique biology of the disease or disorder in question. For children with cancer, it is about understanding each child’s unique cancer at a genetic and biological level, and how it may best be treated. The ultimate aim is to deliver the right treatment to the right child at the right time.
Zero Childhood Cancer
Zero Childhood Cancer is a unique study aiming to show that comprehensive genomic analyses and innovative drug screening can discover treatment options for children that would otherwise not be identified.
By modelling and studying the genetic, epigenetic, and biological changes found in cancer cells, we hope to determine how these changes cause and drive a child’s cancer, improve risk prediction, and identify existing, or develop new, targeted therapies which will work against that cancer. Our findings won’t only benefit individual children with cancer today. They also contribute to our overall understanding of childhood cancer globally, leading to improved health outcomes for all children in the future.
The detailed analysis of each individual child’s cancer generates vast amounts of genomic and biological data. This presents us with an invaluable opportunity not only to identify which treatments may be best suited to that child, but also to better understand childhood cancer in general. In our research, we are continually developing methods to more comprehensively analyse and monitor each child’s cancer. We are also developing new and advanced computational approaches which identify and prioritise clinically relevant genomic alterations − information that may be used to alter a child’s treatment in real time. We also probe the functional molecular biology of tumours so we may better understand how they drive the cancer and what molecules could be targeted to treat the cancer.
We provide bioinformatic expertise to all research teams at Children’s Cancer Institute.
Cancer Epigenetic Biology and Therapeuti...
Our team studies the epigenetics of cancer cells with the aim of designing effective epigenetic-based...
We develop computational approaches to find clinically relevant mutations in cancer cells.
Genomic Childhood Cancer Risk
Our goal is to improve outcomes for children through understanding why children develop cancer.
Translational Tumour Biology
Our Group studies the molecular biology and therapeutic susceptibilities arising from genetic changes...